Vera Therapeutics reported a net loss of $51.7 million for the first quarter of 2025, a significant increase compared to the net loss of $28.4 million in the same period last year. The company is on track to announce pivotal Phase 3 trial results for atacicept in IgAN in Q2 2025 and plans for a BLA submission in Q4 2025.

Vera Therapeutics reported a net loss of $152.1 million for the full year ended December 31, 2024, compared to a net loss of $96.0 million for the prior year. The company ended the year with $640.9 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations through potential approval and U.S. commercial launch of atacicept.

Vera Therapeutics reported a net loss of $46.6 million for the third quarter of 2024. The company completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN and announced an expanded atacicept development program. They also completed a $345 million equity offering.

Vera Therapeutics reported a net loss of $33.7 million, or a net loss per diluted share of $0.62 for the quarter ended June 30, 2024. The company's cash, cash equivalents, and marketable securities totaled $384.4 million as of June 30, 2024.

Vera Therapeutics reported positive 72-week data from the Phase 2b ORIGIN clinical trial and completed a $287.5 million financing. The company's cash and equivalents totaled $403.7 million as of March 31, 2024. Net loss for the quarter was $28.4 million, or $0.56 per share.

Vera Therapeutics reported a net loss of $96.0 million for the year ended December 31, 2023, and had $160.7 million in cash, cash equivalents, and marketable securities as of the same date. The company completed a $287.5 million financing, strengthening its balance sheet.

Vera Therapeutics reported a net loss of $20.1 million for the third quarter ended September 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $159.9 million as of September 30, 2023. The company expects these to fund operations to early 2026.

Vera Therapeutics reported positive 36-week data from the Phase 2b ORIGIN trial and initiated the Phase 3 ORIGIN 3 clinical trial of atacicept in June. The company's balance sheet is expected to fund operations to early 2026. The company reported a net loss of $20.2 million, or $0.46 per share, and cash, cash equivalents, and marketable securities of $181.0 million as of June 30, 2023.

Vera Therapeutics reported a net loss of $30.1 million, or a net loss per diluted share of $0.80 for the quarter ended March 31, 2023. The company's cash, cash equivalents, and marketable securities totaled $197.2 million as of March 31, 2023.

Vera Therapeutics reported a net loss of $89.1 million for the year ended December 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $114.7 million as of December 31, 2022. They are prioritizing advancement of atacicept in IgAN, plans to initiate Phase 3 clinical trial in second quarter of 2023

Vera Therapeutics reported a net loss of $24.7 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $114.4 million as of September 30, 2022. The pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis was initiated.

Vera Therapeutics reported a net loss of $14.9 million for the second quarter of 2022, with $131.9 million in cash, cash equivalents, and marketable securities as of June 30, 2022.

Vera Therapeutics reported a net loss of $17.1 million for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities totaled approximately $151 million as of March 31, 2022. They also have access to a $45.0 million credit facility.

Vera Therapeutics reported a net loss of $16.8 million for the fourth quarter of 2021, with $79.7 million in cash and cash equivalents as of December 31, 2021. The company highlighted the progress of its clinical trials for atacicept and MAU868, and the strengthening of its balance sheet through an equity offering.

Vera Therapeutics reported a net loss of $7.6 million for the third quarter of 2021 and approximately $86.2 million in cash and cash equivalents as of September 30, 2021. The company is making progress in evaluating atacicept.

Vera Therapeutics reported a net loss of $3.4 million, or a net loss per diluted share of $0.33, and cash and cash equivalents of $91.6 million.

Vera Therapeutics reported a net loss of $4.7 million for the first quarter of 2021. The company's cash and cash equivalents were approximately $49.5 million as of March 31, 2021.